Stories
Pharma Q2 Preview: Domestic Demand Boosts Sales Amid US Pressure
M
Moneycontrol•15-10-2026, 16:01
Pharma Q2 Preview: Domestic Demand Boosts Sales Amid US Pressure
- •Companies with strong domestic exposure like Mankind Pharma and Ajanta Pharma are projected to report healthy earnings for the second quarter.
- •Export-heavy players including Cipla, Dr Reddy and Zydus Life are anticipated to experience a decline in profits due to US pricing pressure.
- •Overall pharmaceutical sector sales will be supported by steady domestic demand despite headwinds in overseas markets.
Key Questions Answered
Companies with larger domestic market exposure, such as Mankind Pharma and Ajanta Pharma, are expected to post healthy earnings.
Export-heavy players like Cipla, Dr Reddy's, and Zydus Life are likely to see profits decline due to US pricing pressure, heightened competition, and falling revenues from blockbuster US generics such as Revlimid and Mirabegron.
September marked the strongest month for the Indian Pharmaceutical Market in three years, with sales rising 17.1 percent year-on-year and unit growth accelerating to 5.4 percent.
